This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary HSP90 Therapeutic Antibody Development
HSP90, by stabilizing and activating various cancer-related "client proteins" such as kinases and transcription factors, promotes the survival and proliferation of tumor cells, making it a potential target for the treatment of companion animal cancers. BioVenic offers services for the development of veterinary HSP90 therapeutic antibodies. Our services encompass the entire development process of veterinary therapeutic antibodies, from design and production to purification and characterization, aiding research in the field of companion animal cancer treatment and offering promising therapeutic solutions.
Background of HSP90
| Full Name | Heat shock protein 90 |
| Aliases | HSPC |
| Target Profile | HSP90 is a highly conserved molecular chaperone protein, ubiquitously present in all eukaryotic organisms. As one of the most abundant proteins within the cell, HSP90 constitutes 1-2% of the total cellular protein. It primarily functions in the cytoplasm but is also expressed in the cell nucleus and mitochondria. The main role of HSP90 is to assist in the correct folding of other proteins, stabilize proteins to prevent aggregation, and aid in the degradation of damaged proteins. It plays a crucial role in the activity and stability of a wide variety of signaling proteins, kinases, hormone receptors, and transcription factors. |
MoA of HSP90
HSP90 plays a key role in various processes of tumor progression. It interacts with the hTERT promoter to increase telomerase levels, contributing to the immortalization of cancer cells. HSP90 is closely associated with HIF-1α, which regulates the expression of VEGF, promoting angiogenesis through the VEGF/VEGFR pathway and enhancing the anti-apoptotic capability of cancer cells by strengthening the function of the BCL-2 family of proteins. Another client of HSP90, Akt, promotes the anti-apoptotic actions of cancer cells by downregulating components of the apoptosis mechanism and accelerates tumor growth by hastening the progression of the G1 phase.
Fig.1 Schematic diagram of HSP90 signaling pathways in tumors.1
Application in Veterinary Therapeutics
The upregulation of HSP90 expression and function in cancer cells has been well described. Its client proteins contain various oncogenic proteins, most of which are key transducers in signaling pathways crucial for tumor development and progression, assisting in tumor proliferation, metastasis/invasion, anti-apoptosis, angiogenesis, and treatment resistance. So the activity of HSP90 is generally considered crucial for the survival of companion animal tumor cells, such as in canine mast cell tumors, osteosarcoma, melanoma, and thyroid cancer. Additionally, HSP90 is strongly expressed in feline melanoma, associated with a more malignant tendency, supporting the targeted approach of therapeutic intervention. Inhibiting HSP90 may impact multiple client proteins simultaneously, thereby shutting down several carcinogenic signaling pathways and potentially reversing various malignant behaviors of the tumor.
Veterinary HSP90 Therapeutic Antibody Development Services
Inhibiting the function of HSP90 may represent a promising solution for the treatment of companion animal cancers. BioVenic has established a platform for the development of veterinary HSP90 therapeutic antibodies, encompassing various stages from antibody preparation using diverse technologies to subsequent characterization and modification. We offer multiple antibody preparation technologies, including hybridoma technology, single B cell, and phage display. Our antibody characterization services also include structural and functional characterization, utilizing our advanced instruments to provide accurate antibody characterization results.
For more information about our veterinary HSP90 therapeutic antibody development services, please click the link below.
Why Choose Us?
We provide one-stop services to expedite the development of veterinary therapeutic antibodies.
Our team fine-tunes parameters and methods to ensure the delivery of high-quality antibody characterization outcomes.
Our services in engineering veterinary therapeutic antibodies focus on extending the antibodies' half-life and minimizing immunogenicity risks effectively.
Heat shock proteins are indispensable molecular chaperones regulating various aspects of post-translational protein homeostasis of numerous client proteins, and HSP90 is particularly crucial for the maintenance and stability of known cancer proteins. BioVenic offers veterinary HSP90 therapeutic antibody development services, aiding in exploring the therapeutic potential of HSP targets in combating cancers in canines and felines and seeking new solutions to enhance treatment effectiveness. If you need more information to initiate a collaboration, please feel free to contact us!
References
- Ren, Xiude, et al. "Targeting heat-shock protein 90 in cancer: an update on combination therapy." Cells 11.16 (2022): 2556.
- London, Cheryl A., et al. "Consecutive day HSP90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors." Clinical Cancer Research 24.24 (2018): 6396-6407.